Abstract Search

ba0004oc8 | (1) | ICCBH2015

Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta

Munns Craig , Peacock Lauren , Mikulec Kathy , Kneissel Michaela , Kramer Ina , Cheng Tegan , Schindeler Aaron , Little David

Introduction: Bisphosphonate treatment in children with osteogenesis imperfecta reduces bone catabolism and relies on modelling to form new bone. An anabolic treatment, anti-sclerostin antibody (Anti-SOST Ab), is being investigated in clinical trials. We hypothesized that combined treatment may produce superior outcomes in OI.Methods: Female Col1a2 G610C mice and their wild type littermates (WT) were treated from week 5 to week 9 of life with either sali...

8 shares

ba0005cabs.oc3.4 | Oral Communications | ECTS2016

Anti-sclerostin treatment prevents multiple myeloma bone disease and reduces tumour burden

McDonald Michelle , Reagan Michaela , Terry Rachael , Pettitt Jessica , Le Lawrence , Mohanty Sindhu , Kramer Ina , Kneissel Michaela , Brooks Daniel , Cheng Tegan , Little David , Bouxsein Mary , Rosen Cliff , Ghobrial Irene , Croucher Peter

Multiple myeloma is characterized by extensive bone marrow tumour and destructive osteolytic lesions. Both increased bone resorption and suppressed bone formation result in lesions and pathological fractures. Anti-resorptive therapies prevent further bone loss but patients continue to fracture, arguing for new therapies which increase bone strength. Anti-Sclerostin (Anti-Scl) is a potent stimulator of bone formation, is currently in clinical trials for osteoporosis, however it...

0 shares

Bone Abstracts

Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta

Anti-sclerostin treatment prevents multiple myeloma bone disease and reduces tumour burden

BiosciAbstracts